Atlas Trials

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Clinical trial NCT06712927 · RECRUITING

Trial details

NCT number
NCT06712927
Sponsor
Stanford University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
MelanomaBrain Metastases
Start date
2025-08-06
Primary completion
2026-11-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.